Precision BioSciences DTIL 深 滬
等待開盤 11-07 09:30:00 美东时间
6.44
-0.180
-2.72%
華盛通- 最 高6.66
- 今 開6.66
- 成交量 9.95万股
- 最 低 6.25
- 昨 收 6.62
- 總市值 7590.83万
- 52周最高 8.82
- 市盈率 靜 6.19
- 換手率 0.84%
- 52周最低 3.61
- 委 比 98.06%
- 總股本 1178.70万
- 歷史最高 710.10
- 量 比 0.65
- 振 幅 6.19%
- 歷史最低 4.02
- 每 手 1
- 風險率 0.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Precision BioSciences shares are trading lower after the company reported worse-than-expected Q3 financial results.
Precision BioSciences shares are trading lower after the company reported worse...
11-04 00:51
Precision BioSciences Q3 EPS $(1.84) Misses $(1.34) Estimate, Sales $13.000K Miss $5.400M Estimate
Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(1.84) per share which missed the analyst consensus estimate of $(1.34) by 37.31 percent. This is a 18.22 percent increase over losses of $(2.25) per
11-03 20:01
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
Precision BioSciences Opens First U.S. ELIMINATE-B Site At Massachusetts General Hospital, Actively Recruiting Chronic Hepatitis B Patients
Massachusetts General Hospital, Harvard Medical School, actively recruiting chronic hepatitis B patients along with multiple global clinical trial sites -Phase 1 ELIMINATE-B trial for PBGENE-HBV is progressing and on
10-07 19:16
Precision BioSciences Announces Late-Breaking Poster Presentation At WMS 2025; To Highlight Latest Long-Term Preclinical Efficacy And Durability Data Supporting PBGENE-DMD For Duchenne Muscular Dystrophy Treatment
- Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy-- On track to file an IND and/or CTA by the end of 2025; clinical data
09-30 19:06
Precision Biosciences To Be Issued Us Patent For PBGENE-HBVARCUS Nuclease Utilized In The Company's Lead In Vivo Gene Editing Program, The Us Patent Will Have An Expiration Date In March 2042
Strengthens the Company's intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection into 2042.Phase 1 ELIMINATE-B trial progressing through clinical investigation with dosing of
09-08 19:10
Precision BioSciences Updates Executive Employment Agreements
The latest announcement is out from Precision BioSciences ( ($DTIL) ). On Augus...
09-02 19:50
iECURE Announces It Will Present Additional Data From Its Ongoing OTC-Hope Clinical Trial Of ECUR-506 For Neonatal Onset Ornithine Transcarbamylase Deficiency At Two Upcoming Conferences In Kyoto, Japan
iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies for the treatment of liver disorders with significant unmet need, today announced that
08-25 20:09
Precision BioSciences GAAP EPS of -$2.13 misses by $0.56
Precision BioSciences press release (NASDAQ:DTIL): Q2 GAAP EPS of -$2.13 misses by $0.56. Extended expected cash runway to the second half of 2027 providing more than two years of operating cash More ...
08-07 19:56
Precision BioSciences Q2 EPS $(2.13) Misses $(1.57) Estimate, Sales $18.00K Miss $6.27M Estimate
Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(2.13) per share which missed the analyst consensus estimate of $(1.57) by 35.93 percent. This is a 145.61 percent decrease over earnings of $4.67 per
08-07 19:03
